Alpha 2.0
Login Register
» Articles » PMID: 27387879

All in One: Researchers Create Combination Drugs for Diabetes and Obesity

Overview
Journal Nat Med
Specialties General Medicine
Molecular Biology
Date 2016 Jul 9
PMID 27387879
Citations 5
Authors
Shraddha Chakradhar
Affiliations
Soon will be listed here.
Citing Articles

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.

Ouberai M, Gomes Dos Santos A, Kinna S, Hornigold D, Baker D, Naylor J Front Endocrinol (Lausanne). 2023; 14:1217021.

PMID: 37554763 PMC: 10406450. DOI: 10.3389/fendo.2023.1217021.

Prediction of drug combination effects with a minimal set of experiments.

Ianevski A, Giri A, Gautam P, Kononov A, Potdar S, Saarela J Nat Mach Intell. 2020; 1(12):568-577.

PMID: 32368721 PMC: 7198051. DOI: 10.1038/s42256-019-0122-4.

Battle of GLP-1 delivery technologies.

Yu M, Benjamin M, Srinivasan S, Morin E, Shishatskaya E, Schwendeman S Adv Drug Deliv Rev. 2018; 130:113-130.

PMID: 30009885 PMC: 6843995. DOI: 10.1016/j.addr.2018.07.009.

Ghrelin regulation of glucose metabolism.

Poher A, Tschop M, Muller T Peptides. 2018; 100:236-242.

PMID: 29412824 PMC: 5805851. DOI: 10.1016/j.peptides.2017.12.015.

Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly.

Ouberai M, Gomes Dos Santos A, Kinna S, Madalli S, Hornigold D, Baker D Nat Commun. 2017; 8(1):1026.

PMID: 29044101 PMC: 5647335. DOI: 10.1038/s41467-017-01114-1.

References
1.
Rubino F, Nathan D, Eckel R, Schauer P, Alberti K, Zimmet P . Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016; 39(6):861-77. DOI: 10.2337/dc16-0236. View
2.
Finan B, Yang B, Ottaway N, Smiley D, Ma T, Clemmensen C . A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2014; 21(1):27-36. DOI: 10.1038/nm.3761. View
3.
Bagger J, Holst J, Hartmann B, Andersen B, Knop F, Vilsboll T . Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. J Clin Endocrinol Metab. 2015; 100(12):4541-52. DOI: 10.1210/jc.2015-2335. View
4.
Day J, Ottaway N, Patterson J, Gelfanov V, Smiley D, Gidda J . A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009; 5(10):749-57. DOI: 10.1038/nchembio.209. View
5.
Finan B, Ma T, Ottaway N, Muller T, Habegger K, Heppner K . Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013; 5(209):209ra151. DOI: 10.1126/scitranslmed.3007218. View